ClinicalTrials.gg
Enrolling by invitationNCT07521683Updated Apr 13, 2026

A Phase II Clinical Study to Evaluate the Efficacy and Safety of NS-136 in the Treatment of Schizophrenia

A Phase 2 interventional study of NS-136 in Schizophrenia(Acute), sponsored by NeuShen Therapeutics. Enrolling by invitation at 1 site in China. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2026-04-13.

Sponsored by NeuShen Therapeutics · Phase 2, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
150
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 252 studies in Schizophrenia with a site in China — 64 open to participants now, 68 under way, 4 of them phase 3. Schizophrenia · China.

Planned enrollment
80th of 216
150 · median 100
Started
2025
with 15 others
Phase 2
10 of 252
4 open now
Primary completion
2026-11
later than 29 of 67 live
Registered
216th of 252
by date

Among the 252 studies in Schizophrenia with a site in China, this one is the 80th largest by planned enrollment of the 216 interventional ones that give a count, is one of 16 that started in 2025, is one of 10 in phase 2, reaches primary completion later than 29 of the 67 other live ones, and was the 216th registered.

Schizophrenia

3,574 studies on the registry are indexed under Schizophrenia; 494 are open to participants now.

Browse Schizophrenia studies →

Open to participants now

64 of the 252 studies in Schizophrenia with a site in China are open now. Recruiting first, the newest first:

59 more — sign in →

All 64 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 333 Schizophrenia studies recruiting now, 63 (19%) set no upper age limit and 258 (77%) stop at 75 or younger; 42 take children under 18; 83 take healthy volunteers.

This study: 18 Years to 65 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 252 studies in Schizophrenia with a site in China, or all of them as a file.
02

Study summary

This is a randomized, double-blind, placebo-controlled, parallel-group Phase II study to preliminarily evaluate the efficacy and safety of NS-136 in patients with schizophrenia. The study consists of a screening period, baseline period, treatment period, and follow-up period, with the screening period lasting up to 21 days.

Eligible subjects will be randomized in a 1:1:1 ratio to the 80 mg (QD) group, 120 mg (QD) group, or placebo group. The study drug treatment will last for 5 weeks, followed by a 2-week safety follow-up after completion of the study.

03

Conditions studied

  • Schizophrenia(Acute)

Browse trials for

Keywords

  • NS-136
  • NeuShen
04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Male or female aged 18-65 years (inclusive) with (BMI) of 18-34 kg/m2 (inclusive);
  2. No participation in other clinical studies within 60 days prior to signing the form (ICF);
  3. Patients diagnosed with schizophrenia according to criteria;
  4. During the screening and baseline periods, subjects should have a PANSS total score of 80 or above, CGI-S score of 4 or above, moderate-to-severe illness severity, and at least 2 positive symptoms;
  5. Trial participants are willing to discontinue all prohibited antipsychotic medications in order to meet the required by the study protocol;
  6. Trial participants are in a state of relapse or acute exacerbation of psychotic symptoms prior to signing the ICF;
  7. Women of must have a negative serum pregnancy test during the screening period. All subjects should agree to use effective (see Appendix 1 for details) from the time of signing the ICF until at least 3 months after the last dose of the study drug, with no plans for sperm or egg donation;
  8. Subjects should fully understand the study objectives, nature, procedures, and potential adverse reactions, voluntarily participate as subjects, and sign the ICF before any study procedures are initiated.

Exclusion criteria

Exclusion Criteria:

  1. Diagnosis: Subjects with the following psychiatric diagnoses should be excluded, including but not limited to intellectual disability, schizoaffective disorder, schizotypal disorder, depressive psychosis, major depressive disorder, bipolar disorder, post-traumatic stress disorder, generalized anxiety disorder, obsessive-compulsive disorder, eating disorders (bulimia nervosa, anorexia nervosa) or other anxiety disorders (except anxiety symptoms secondary to schizophrenia); dementia, dementia-like symptoms, amnesia or other cognitive disorders; borderline personality disorder, paranoid personality disorder, histrionic personality disorder, schizoid personality disorder, apathetic personality disorder or antisocial personality disorder;
  2. Subjects with treatment-resistant schizophrenia who have shown no response or improvement after receiving adequate doses (clinically tolerable effective doses) of two different classes of antipsychotic drugs for a minimum treatment duration of 6 weeks; or subjects who are unresponsive to clozapine treatment or responsive only to clozapine treatment;
  3. Subjects with unstable extrapyramidal symptoms requiring dose adjustments and/or new medication treatments within 6 months prior to signing the ICF;
  4. Subjects with current or past history of significant pulmonary, gastrointestinal, renal, hepatic, metabolic, endocrine (including newly diagnosed diabetes or known diabetes with >7.5%), hematologic, immunologic, psychiatric (except schizophrenia), or neurological disorders, dysphagia, or to the study drug or any of its components;
  5. Subjects with current or past history of major cardiovascular diseases, including any of the following: ischemic heart disease, myocardial infarction, valvular heart disease, cardiac surgical revascularization (coronary artery bypass grafting, stent placement or percutaneous transluminal coronary angioplasty), hypertension, receiving antihypertensive medications, orthostatic hypotension, angina pectoris, unstable angina, cerebrovascular accident or stroke or , pacemaker, atrial fibrillation, flutter or nonsustained or sustained ventricular tachycardia, pulmonary hypertension, sick sinus syndrome, second- or third-degree atrioventricular block, congestive heart failure, personal or family history of sudden death or long syndrome, unexplained syncope or syncope within the past 3 years;
  6. Subjects presenting with first-episode schizophrenia symptoms as judged by the investigator;
  7. Subjects who, in the investigator's judgment, have exhibited acute depressive symptoms within the last 30 days requiring antidepressant treatment;
  8. Subjects with a history of epilepsy or seizures, excluding single seizure episodes (e.g., childhood febrile seizures) or seizures associated with trauma or alcohol withdrawal;
  9. Subjects with central nervous system infections, demyelinating diseases, progressive neurological disorders, intellectual disability, or any central nervous system condition deemed progressive;
  10. Subjects who have received systemic electroconvulsive therapy within 60 days prior to screening;
  11. Subjects who answer "Yes" to item 4 of the C-SSRS suicidal ideation section (active suicidal ideation without specific plan) with the most recent episode meeting this C-SSRS item 4 criterion occurring within the past 6 months, as well as those who answer "Yes" to item 5 of the C-SSRS suicidal ideation section (active suicidal ideation with specific plan and intent);
  12. Subjects with positive results in any of the following screening tests: surface antigen (HBsAg), virus antibody (Anti-HCV), antibody (Anti-HIV), or serological testing for syphilis antibody;
  13. Subjects with any of the following abnormal clinical laboratory test results during the screening period (one retest is permitted at the investigator's discretion):

    • or ALT ≥3×
    • Total ≥2×ULN
  14. Subjects with alcohol abuse or weekly alcohol consumption exceeding 14 units (1 unit equals 17.5 mL or 14 g pure alcohol; alcohol content of different beverages is labeled by volume percentage; 1 alcohol unit approximately equals 35 mL of 50° liquor or 350 mL of 5° beer) within 4 weeks prior to screening;
  15. Subjects with a history of drug abuse within 1 year prior to the first dose, or positive results in the multi-drug test panel (urine) during screening (except for benzodiazepines);
  16. Subjects who have used moderate or strong inducers or inhibitors within 2 weeks prior to the first dose, or are expected to require moderate or strong CYP3A4 inducers or inhibitors during study participation;
  17. Subjects deemed by the investigator to have other factors unsuitable for study participation.
Terms in these criteria, in plain language(17)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

DSM diagnostic criteria

The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.

Washout period

A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Investigator, Outcomes assessor)
Enrollment
150 participants (estimated)

Study arms

  • Experimental
    80 mg NS-136

    Drug: NS-136

  • Experimental
    120 mg NS-136

    Drug: NS-136

  • Placebo comparator
    Placebo

    Drug: NS-136

Interventions

  • DrugNS-136

    NS136 80mg and 120mg

06

What researchers measure

Primary outcomes

  1. Positive And Negative Syndrome Scale(PANSS )score

    PANSS consists 3 sub-scales with 30 questions, The scoring range for each question is from 1 (no symptoms) to 7 (extremely severe symptoms).

    Time frame: Week 5

Secondary outcomes

  1. PANSS positive symptom score;

    PANSS positive symptom includes 7 questions, The scoring range for each question is from 1 (no symptoms) to 7 (extremely severe symptoms)

    Time frame: Week 5

  2. PANSS negative symptom

    PANSS negative symptom includes 7 questions, The scoring range for each question is from 1 (no symptoms) to 7 (extremely severe symptoms)

    Time frame: Week 5

  3. Clinical Global Impression-Severity (CGI-S)

    Considering your total clinical experience with this patient population, how ill is the patient at this time, scoring from 0 (not assessed) to 7 (among the most extremely ill patients).

    Time frame: week 5

  4. Clinical Global Impression-Improvement(CGI-I)

    Compared to his/her condition at baseline, how much has he/she changed, scoring from 0(not assessed) to 7 (very much worse)

    Time frame: week 5

  5. Extrapyramidal Symptom (EPS) rating scales

    Extrapyramidal Symptom (EPS) rating scales in this study includes 3 scales: Simpson-Angus Scale (SAS) consists of 10 items, scoring from 0(normal) to 4 (Sever); Abnormal Involuntary Movement Scale (AIMS) examination consists of 12 items that rate involuntary movements in various body regions. Each item is scored on a 5-point severity scale from 0 to 4, where 0 = none, 1 = minimal, 2 = mild, 3 = moderate, and 4 = severe; Barnes Akathisia Rating Scale (BARS) Patient should be observed while they are seated, and then standing while engaged in neutral conversation (for a minimum of two minutes in each position). Objective phenomena scoring from 0 (normal) to 3 (serve), Subjective phenomena scoring from 0 (Absence of inner restlessness) to 3(sever), Global clinical assessment of akathisia phenomena scoring from 0(absent) to 5 (Severe akathisia).

    Time frame: week 5

  6. Columbia-Suicide Severity Rating Scale(C-SSRS)

    Assess suicidal ideation and behavior at different time points. The result shows as "yes" or "No"

    Time frame: week 5

  7. Adverse Events(AE)

    Adverse events and laboratory safety evaluations during the study

    Time frame: week 7

07

Study locations

1 site
  • NeuShen
    Shanghai, China
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Oct 2025 (actual). Primary completion is estimated for Nov 2026, 13 months after the start.

Of 57 industry-sponsored phase 2 interventional studies under Schizophrenia, half reached primary completion within 20 months of starting (the median), counting those still running; a quarter within 12 and three quarters within 32. This study's planned 13 months is below that.

Counting every sponsor, half of 101 studies reached it within 25 months; a quarter within 15 and three quarters within 42.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 11, 2025
First posted
Apr 13, 2026
StartActual
Oct 20, 2025
Primary completionEst.
Nov 2026
CompletionEst.
Dec 2026
Last update
Apr 13, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 13, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07521683
Lead sponsor
NeuShen Therapeutics
Responsible party
Sponsor
First posted
Apr 13, 2026
Start date
Oct 20, 2025
Primary completion
Nov 2026 (estimated)
Completion
Dec 2026 (estimated)
Last update
Apr 13, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

No contact was published for this record. The registry link below has the sponsor’s details.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion